Café

300558

56.152.35%( -1.35 )

LongbridgeAI

300558

56.152.35%( -1.35 )

BETTA PHARMACEUTICALS: The company is accelerating the overseas commercial plan for ensartinib

Zhitong

Jul 4, 2025 at 03:45 AM

On July 4th, BETTA PHARMACEUTICALS stated on the interactive platform that the company is currently accelerating the overseas commercial plan for ensartinib, actively exploring promotional models that comply with local regulations and market demands to achieve drug accessibility and maximize company interests

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Related Stocks

BETTA PHARMACEUTICALS

SZ300558

-2.35%

贝达药业

HK0BDYY

LongbridgeAI

BETTA PHARMACEUTICALS: The company is accelerating the overseas commercial plan for ensartinib

Zhitong

Jul 4, 2025 at 03:45 AM

Source: Zhitong The copyright of this article belongs to the original author/organization.

Related Stocks

BETTA PHARMACEUTICALS

SZ300558

-2.35%

贝达药业

HK0BDYY